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 To address inconsistencies in the recognition and manage-
ment of acute kidney injury (AKI), an electronic-alert (e-alert) 
system was  implemented by NHS England in 2015. This study 
aimed to describe its impact within acute medicine in the West 
 Midlands. All admissions to included acute medical units were 
screened for AKI in two phases, before and after the e-alert 
was introduced. Data describing recognition and manage-
ment of patients with AKI were collected. In the 10 units that 
participated in both phases, recognition of AKI by clinicians 
signifi cantly improved from 67.9% in 2015 to 76.1% in 2016 
(p=0.04). Further analysis of the data found that the presence 
of an e-alert had a limited effect on recognition and manage-
ment, suggesting it was not the primary cause of the improve-
ments. Multiple avenues of research have been recommended 
to clarify the impact of the e-alert system and to improve 
defi ciencies in management that were identifi ed in the data. 
 KEYWORDS :  Acute kidney injury ,  defi nition ,  recognition ,  acute 
medicine ,  e-alert 
 Introduction 
 Acute kidney injury (AKI) is under-recognised and flaws in 
management are noted when it is identified. 1–3 This is a concern as 
the diagnosis of AKI is associated with a significant mortality; even 








Furthermore, the prevalence of AKI has been reported to be as 
high as 18% in acute hospital admissions. 4,6 
 Consensus statements 3,7 and guidelines 8,9 recommend urinalysis, 
renal ultrasound, drug dose adjustments and avoidance of 
nephrotoxic medications during the early management of AKI. 
Intravenous fluid should be considered for all cases. However, if 
not required, aggressive fluid therapy is harmful 10 so a preceding 
fluid assessment is essential. Studies exploring the impact of such 
management steps have shown a reduction in the incidence and 
severity of AKI. 3,11,12 
 To improve the management of patients with AKI, electronic-
alert (or ‘e-alert’) systems have been recommended to support 
recognition. The benefit of such systems remains unclear. Some 
studies demonstrated success in changing clinician behaviour and 
patient outcome. 13–16 Others failed to do so. 17 A systematic review 
of six studies found AKI e-alert systems did not improve survival or 
reduce renal replacement therapy utilisation. 18 
 Despite this uncertainty, an e-alert system for AKI was 
implemented throughout the NHS in England. 19 An automated 
screening process reports AKI and its stage alongside the 
creatinine result. It is driven by an algorithm based on NICE clinical 
guideline CG169. 8 This guidance aimed to improve the recognition 
and management of AKI, particularly in the initial stages, and 
focused on generalist specialties such as acute medicine to 
maximise their impact. The guidelines used the Kidney Disease: 
Improving Global Outcomes (KDIGO) classification 7 to identify AKI 
based on increases in creatinine or reductions in urine output. The 
target date for nationwide implementation of the e-alert was 9 
March 2015. 
 The aim of this study was to describe the recognition and 
management of AKI in the West Midlands before and after the 
implementation of the NHS AKI e-alert system. A secondary 
aim was to describe how severity (defined by KDIGO stage) was 
associated with recognition and management. 
 Method 
 This observational study was reported according to the 
‘Strengthening the Reporting of Observational Studies in 
Epidemiology’ (STROBE) statement. 20 A protocol was designed 
in advance and agreed by all members of the West Midlands 
Acute Medicine Collaborative (WAM-C): a trainee-led research 
collaborative. 21 
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to the study lead for analysis. Apparent differences were tested 
using χ 2 test where appropriate. 
 Results 
 2,791 patients were screened in 14 AMUs across the West 
Midlands during phase one. 354 AKI cases were identified, giving 
an estimated prevalence of AKI in acute medical admissions of 
12.7% (95%, confidence interval = 11.5–14.0). In phase two, 265 
AKI cases were identified across 11 AMUs. A total of six patients 
were approaching the end of life and so were excluded from 
analysis: two in phase one, four in phase two. Age, gender and 
criteria used to diagnosed AKI were comparable between the two 
phases (see Table  2 ). 
 As summarised in Table  3 , 73.4% of AKI cases across both 
phases had a documented diagnosis, the proxy for clinical 
recognition. Urinalysis and volume assessment were performed in 
50.2% and 54.3% of AKI cases, respectively. When a patient was 
taking a nephrotoxic medication, it was stopped in 81.5% of cases 
and, when an ultrasound was deemed necessary by the study 
team, it was requested in 64.4% of cases. 
 The study was registered as an audit at each site in the West 
Midlands. Data were collected prospectively in two phases, before 
and after implementation of the e-alert system, on six separate 
days as determined by local site team at each site. The on-call 
medical team were unaware of the study prior to completion. 
 Phase one took place between 2 February and 16 March 2015 
at 14 hospital sites. All data were collected before the e-alert 
system was active at each site. Phase two took place at 11 
hospital sites between 1 April and 22 May 2016, 1 year following 
implementation of the e-alert system. Ten sites were involved in 
both phases of data collection. 
 All patients admitted onto the acute medical unit (AMU) during 
each collection day were manually screened for AKI. Medical 
patients admitted directly to other wards, including intensive 
care, were not included in the study. Numbers of patients without 
AKI were recorded in phase one to calculate prevalence. AKI 
was defined according to the KDIGO definition. 7 As per 2011 
Renal Association guidelines, 9 and recent articles, 22–25 baseline 
creatinine was defined as the lowest creatinine level recorded 
within 3 months. If a 3-month creatinine was not available, then 
AKI was not diagnosed, assuming other criteria were not met. 
This was with the aim of maximising specificity, ie ensuring all 
identified cases had AKI rather than chronic kidney disease (CKD): 
defined by KDIGO as a decline in kidney function for >3 months. 26 
 Recognition of AKI by clinicians was determined by the presence 
of a documented diagnosis of AKI in the medical records. Clinical 
recognition or recognition by the e-alert system was calculated as 
a percentage of AKI identified by the study team. The successful 
completion of four management strategies within the first 24 
hours (see Table  1 ) was also based on medical records alone. If a 
variable was not recorded, it was assumed the standard had not 
been met. The stage of each AKI was recorded in phase two only. 
 Data were recorded on a standardised Microsoft Excel 2010 
spreadsheet by the local site team, anonymised and then returned 
 Table 1.  Study criteria 
Standard Criteria to meet standard 
1.  Recognition 
of AKI
If a diagnosis of AKI is documented in the 
initial clerking or senior review.
2.  Nephrotoxic 
medication 
stopped
If a nephrotoxic medication that was 
prescribed before the AKI diagnosis had 
been stopped. Answer ‘N/A’ if the patient is 
not on a nephrotoxic medication.
3.  Urinalysis 
performed
If a urinalysis result was documented in the 
medical records. Answer ‘N/A’ if the patient 
is anuric or awaiting an intervention to drain 
urine.




Answer ‘N/A’ unless the cause of AKI is 
unknown or is likely to be obstruction based 
on the medical records. Standard met if a 
renal ultrasound request made.
5.  Volume 
assessment
If any documentation of volume status is 
found in the medical records (including terms 
such as dry, overloaded, dehydrated).
 This is a list of the audit standards used to assess the recognition and 
management of AKI as described in the study protocol. AKI = acute kidney 
injury. 
 Table 2.  Characteristics of AKI cases in phase one 
and phase two 












Creatinine rise ≥50% 
increase from baseline
Creatinine rise ≥26 





Urine output <0.5 mL/
kg/hr over 6 hours
2 (<1) 0 (0)
 This table compares the age, gender and chosen diagnostic criteria for AKI 
between phase one and phase two. AKI = acute kidney injury; SD = standard 
deviation. 
 Table 3.  Overall recognition and management of 
AKI by clinicians 
 Total Documented Not 
documented 
Number (%) 613 (100) 450 (73.4) 163 (26.5)
Volume assessment, 
n (%)
333 (54.3) 271 (60.2) 62 (38.0)
Urinalysis, n (%) 302 (50.2) 242 (54.3) 60 (38.5)
Nephrotoxics 
stopped, n (%)
326 (81.5) 272 (88.0) 54 (59.3)
Ultrasound 
requested, n (%)
94 (64.4) 87 (74.4) 7 (24.1)
 This table illustrates the number and percentage of AKI cases that were 
documented and appropriately managed using combined data from phase 
one and phase two. AKI = acute kidney injury. 
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 There was a significant improvement in all management 
standards if AKI was documented by the clinical team. Three 
of the standards showed a 50% increase: volume assessment 
(χ 2 = 23.74; p=<0.0001), urinalysis (χ 2 = 11.54; p=0.0006), and 
nephrotoxics stopped (χ 2 = 38.36; p=<0.0001). A renal ultrasound 
request, when appropriate, was three times more likely with a 
documented diagnosis (χ 2 = 25.56; p=<0.0001). 
 During phase two, the stage of AKI was recorded. 55.1%, 24.6%, 
and 20.3% were noted to have stage 1, 2 and 3 respectively (see 
Table  4 ). Stage 1 AKI was the least likely to be documented. Stage 
2 and 3 were both documented in approximately 90% of cases. 
These differences in documentation were significant (χ 2 = 28.22; 
p=<0.0001). The stage of AKI had an impact on management 
standards that differed from its impact on documentation. 
With the exception of ultrasound requesting, all management 
standards were more likely to be performed for AKI stage 3 than 
AKI stage 2. However, none of these differences was significant in 
isolation. 
 Comparisons between phase one and two were restricted to 
the 10 hospitals that participated in both phases to better match 
patient populations and working practices at the same sites. This 
decision was made following data collection. As shown in Table  5 , 
the proportion of documented AKI cases significantly increased 
between phase one and phase two (χ 2 = 4.03; p=0.04). This 
increase was also seen for volume assessment (χ 2 = 4.31; p=0.04) 
and urinalysis (χ 2 = 7.50; p=0.006). 
 To analyse the impact of the e-alert system on these changes, 
AKI cases with and without an e-alert, and with and without a 
documented diagnosis were compared in phase two (see Table  6 ). 
The proportion of AKI identified by the e-alert system (74.3%) 
was similar to the proportion documented by clinicians (74.7%). 
However, recognition was discordant between clinicians and the 
e-alert system in one in three cases of AKI. Of note, the presence 
of an e-alert was not associated with a significant improvement 
in documentation or management standards, with the exception 
of ultrasound requesting (χ 2 = 7.56; p=0.006). This was in contrast 
 Table 4.  Recognition and management of acute 
kidney injury by severity 
Stage of AKI Stage 1 Stage 2 Stage 3 
Number (%) 147 (62.8) 63 (26.9) 51 (21.8)
Documented, n (%) 92 (62.5) 58 (92.1) 46 (90.2)
E-alert present, n (%) 96 (65.3) 53 (84.1) 45 (88.2)
Volume assessment, n (%) 79 (53.7) 39 (61.9) 37 (72.5)
Urinalysis, n (%) 74 (52.5) 34 (54.8) 35 (71.4)
Nephrotoxic medications 
stopped, n (%)
71 (77.1) 36 (85.7) 33 (94.3)
Ultrasound requested, n (%) 10 (38.5) 12 (92.3) 17 (85.0)
 This table describes the prevalence of stage 1, 2 and 3 AKI, the proportion 
of cases recognised by clinicians and the e-alert system, and the variation in 
management for each severity. AKI = acute kidney injury. 
 Table 5.  Changes in recognition and management 
between phase one and phase two 
 Phase one Phase two 
Number of AKI cases 262 234
Documented, n (%) 178 (67.9) 178 (76.1)
Volume assessment, n (%) 129 (49.2) 137 (58.5)
Urinalysis, n (%) 109 (41.8) 124 (54.1)
Nephrotoxic medications stopped, 
n (%)
143 (80.8) 128 (83.1)
Ultrasound requested, n (%) 47 (65.3) 35 (63.6)
 This table describes the changes in clinical recognition and management 
between phase one and phase two. The data are only taken from the 
10 hospitals that were involved in both phases of the study to allow direct 
comparisons to be made. AKI = acute kidney injury. 
 Table 6.  The variation in recognition and management depending on the presence of a documented 
diagnosis and an e-alert 
 Phase two total e-alert No e-alert Documented Undocumented Both Neither 
Number of AKI cases (% of 
total AKI cases)
234 179 (76.5) 55 (23.5) 178 (76.1) 56 (23.9) 138 (59) 15 (6.4)
Documented, n (% of total 
AKI cases)
178 (76.1) 138 (77.1) 40 (72.7) 178 (100) 0 (0) 138 (100) 0 (0)
Volume assessment, n (% of 
total AKI cases)
137 (58.5) 105 (58.7) 32 (58.2) 117 (65.7) 20 (35.7) 91 (65.9) 6 (40)
Urinalysis, n (% unless anuric) 124 (54.1) 98 (56.3) 26 (47.3) 99 (56.6) 25 (46.3) 76 (56.2) 3 (20)
Nephrotoxic medications 
stopped, n (% of total patients 
on nephrotoxic medication)
128 (83.1) 97 (82.9) 31 (83.8) 109 (90.1) 19 (57.6) 85 (90.4) 7 (70)
Ultrasound requested, n (% 
when ultrasound is indicated)
35 (63.6) 30 (73.2) 5 (35.7) 34 (70.8) 1 (14.3) 29 (78.4) 0 (0)
 This table lists the proportion of AKI cases in phase two with and without an e-alert, and with and without a documented diagnosis, and describes how the 
recognition and management differ between these subgroups. AKI = acute kidney injury; e-alert = electronic-alert. 
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to the presence of a documented diagnosis, which continued to 
be associated with a significant increase in all four management 
standards in this dataset, apart from urinalysis. The presence of 
both an e-alert and a documented diagnosis was not associated 
with a significant change to any of the four management 
standards compared with a documented diagnosis alone. 
 Discussion 
 This multicentre study explored the recognition and management 
of AKI by clinicians in AMUs across the West Midlands and how 
these standards changed following the implementation of the 
NHS AKI e-alert system in 2015. While there was a significant 
improvement in the recognition and management of AKI between 
phase one and phase two, further analysis of the data suggested 
this was not due to the e-alert system. 
 AKI was frequently missed by clinicians; a documented 
diagnosis was absent in one in every four cases. Analysis of AKI 
management found similar deficiencies. Both urinalysis and 
volume assessment were absent from one in two medical records, 
one in three cases did not have an ultrasound request when 
appropriate, and nephrotoxic medications were not stopped for 
one in five patients when relevant. 
 In addition, the data support the view that recognition by itself 
is not the answer. Even for documented diagnoses, deficiencies 
were noted. This was particularly true for volume assessment, 
completed in 60.2% of documented AKI cases, and urinalysis, 
completed in 54.3% of documented cases. Volume assessment 
is acknowledged to be challenging, 27 so any comment and 
examination linked to volume or fluid balance were accepted, 
setting a low bar. The failure to meet this standard is a concern 
given the harm that unnecessary intravenous fluid can cause. 10 
Moreover, this study only identified community-acquired AKI. 
Because the quality of care is worse for patients who develop AKI 
after admission (ie hospital-acquired AKI), 2 the above failures in 
recognition and management could be an overestimate. 
 Recognition and management varied with stage of AKI. Nearly 
one in three cases of stage 1 AKI had no documented diagnosis. 
In contrast, only one in ten cases of stage 2 and 3 AKI were not 
documented. Management was also better for more severe stages 
of AKI. Of note, the management of stage 3 AKI appeared to 
be better than that of stage 2. However, these differences were 
not significant. The lower documentation rates for stage 1 AKI 
could reflect the failure of clinicians to recognise the condition. 
Alternatively, clinicians may fail to document a diagnosis because 
they underestimated its significance. This would explain why 
a proportion of patients with undocumented AKI were still 
appropriately managed and might explain the possibility that 
stage 3 AKI is managed better than stage 2 despite identical 
documentation rates. The breakdown of AKI by stage was similar 
to the breakdown of AKI severity found in other studies. 28 
 Between phase one and phase two, there was a significant 
improvement in documentation and in two of the four 
management standards (volume assessment and urinalysis). 
However, while a documented diagnosis was associated with 
improvements in three management steps, an e-alert was 
only associated with improvements in ultrasound requesting. 
Furthermore, the documented diagnosis and e-alert disagreed 
in one in three cases. These findings suggest improvements in 
management were not linked to the e-alert, and that the e-alert 
system is having a limited impact upon clinical decision making. 
Alert fatigue is a well-recognised phenomenon which offers a 
possible explanation. An interventional study of an AKI-alert 
system noted 78.1% of interruptive alerts were deferred by 
clinicians. 29 Because the NHS e-alert is not interruptive, its impact 
is likely to be lower and a higher proportion of e-alerts might be 
ignored. The many other campaigns, quality improvement projects 
and care bundles that have been completed since the AKI-themed 
National Confidential Enquiry into Patient Outcome and Death 
(NCEPOD) report in 2009 2 and NICE AKI guidelines in 2013 8 may 
all have contributed to the improvements seen between phase 
one and phase two. 
 By excluding patients who had no creatinine result within the last 
3 months, some AKI cases will have been excluded from this study. 
This offers an explanation for the AKI prevalence of 12.7%, lower 
than the 17.7% found in a similar UK study performed in AMUs. 30 
The choice of baseline did maximise the specificity of the AKI 
definition, however, and limited the inclusion of patients with a 
progression of CKD. As a result, all identified AKI cases should have 
been recognised as AKI by clinicians and the e-alert system and 
managed appropriately. 
 The e-alert's algorithm (based on that described in the NICE 
guidelines) 8 defines the baseline creatinine using the lowest 
creatinine result in the last 7 days or the median of all results 
within the last year. When creatinine rises occur in the preceding 
12 months, this approach can miss AKI, which may explain the 
high proportion of stage 1 AKI that was missed by the e-alert 
system. Currently, there is a limited evidence base to support any 
definition of the baseline creatinine, which is acknowledged in the 
literature 22,31 and by KDIGO. 7 
 A further limitation of this study was the decision to judge the 
standards solely based on documentation. The recognition of 
AKI by clinicians was assumed to be equivalent to a documented 
diagnosis. However, it is likely that documentation was forgotten 
on occasion despite the clinician being aware of the AKI. 
 This study highlights multiple avenues for research. Exploring 
the decision-making process that leads to a clinical diagnosis of 
AKI could provide multiple benefits; identifying knowledge gaps 
for all grades of clinician, understanding the interaction between 
clinicians and the e-alert algorithm, and defining how experienced 
clinicians determine the baseline creatinine, perhaps offering a 
new approach for further study. Subsequent research to support 
a single definition of the baseline creatinine would provide an 
evidence base to support future AKI guidelines. Addressing 
this issue is particularly important as even a small increase in 
creatinine causes mortality to rise. 32 
 Finally, future studies that explore why each management 
standard was not completed would allow improvement measures 
to be appropriately designed and targeted. For example, a 
number of issues could prevent a urinalysis from being performed, 
including patient incontinence, a lack of equipment or staff, or a 
communication failure. 
 Conclusion 
 The AKI e-alert system and the algorithm that drives it remains 
a cornerstone of NHS policy. However, evidence to support its 
impact is lacking. While this study did note an improvement in 
AKI recognition and management between phase one and phase 
two, this change did not seem to be linked to the e-alert system. 
Furthermore, the documentation of AKI by clinicians did not 
appear to be linked to the presence of an e-alert. Several avenues 
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of research have been identified that should be explored before 
further attempts to improve the recognition and management 
of AKI are made. Addressing these research aims should be a 
priority given the ongoing deficiencies in the recognition and 
management of AKI identified in this study. ■ 
 Supplementary material 
 Additional supplementary material may be found in the online version 
of this article at  www.clinmed.rcpjournal.org : 
 S1 – Authorship. 
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